Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cbd + thc-Johns Hopkins University refers to research-grade vaporized cannabis formulations containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) utilized in Phase 1 clinical trials by Johns Hopkins University's Behavioral Pharmacology Research Unit. These formulations are primarily used to evaluate the physiological and behavioral responses, including subjective drug effects and cognitive performance, in healthy occasional cannabis users. THC acts as a partial agonist at the cannabinoid CB1 and CB2 receptors, mediating psychoactive and analgesic effects, while CBD functions as a negative allosteric modulator of the CB1 receptor and interacts with various other targets such as 5-HT1A and TRPV1. The cannabis material for these studies is typically sourced from the National Institute on Drug Abuse (NIDA) Drug Supply Program. The research is designed for pharmacodynamic characterization in controlled laboratory settings rather than for the treatment of specific clinical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cbd + thc-Johns Hopkins University.